-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25

Benzinga·08/05/2026 16:00:25
Listen to the news
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.